XBiotech Inc. (XBIT): Price and Financial Metrics

XBiotech Inc. (XBIT): $6.73

0.10 (+1.51%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add XBIT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#210 of 360

in industry

XBIT Price/Volume Stats

Current price $6.73 52-week high $7.24
Prev. close $6.63 52-week low $3.05
Day low $6.65 Volume 6,075
Day high $6.73 Avg. volume 43,936
50-day MA $5.57 Dividend yield N/A
200-day MA $4.89 Market Cap 204.84M

XBIT Stock Price Chart Interactive Chart >

XBIT POWR Grades

  • XBIT scores best on the Growth dimension, with a Growth rank ahead of 47.28% of US stocks.
  • The strongest trend for XBIT is in Growth, which has been heading down over the past 77 days.
  • XBIT's current lowest rank is in the Momentum metric (where it is better than 7.67% of US stocks).

XBIT Stock Summary

  • The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about just 0.22% of US stocks.
  • With a price/sales ratio of 435.25, XBIOTECH INC has a higher such ratio than 98.93% of stocks in our set.
  • Revenue growth over the past 12 months for XBIOTECH INC comes in at -96.35%, a number that bests merely 1.04% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to XBIOTECH INC, a group of peers worth examining would be RVMD, CKPT, NRIX, XNCR, and IDYA.
  • Visit XBIT's SEC page to see the company's official filings. To visit the company's web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • In comparison to the median Healthcare stock, XBIT's price/sales ratio is 18340.91% higher, now standing at 405.7.
  • Over the past 106 months, XBIT's EV/EBIT ratio has gone up 34.9.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2023-12-29 405.7 0.5 -5.3 3.6
XBIT 2023-12-28 402.7 0.5 -5.2 3.7
XBIT 2023-12-27 405.7 0.5 -5.3 3.6
XBIT 2023-12-26 398.7 0.5 -5.2 3.7
XBIT 2023-12-22 397.7 0.5 -5.2 3.7
XBIT 2023-12-21 404.7 0.5 -5.2 3.6

XBIT Growth Metrics

    The year over year cash and equivalents growth rate now stands at -3.36%.
  • Its 2 year price growth rate is now at -58.56%.
  • Its 5 year price growth rate is now at 62.32%.
XBIT's revenue has moved up $8,210,000 over the prior 67 months.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.21 -19.286 -36.164
2022-06-30 11.049 -16.661 -26.767
2022-03-31 14.044 62.513 -20.241
2021-12-31 18.394 69.445 -17.414
2021-09-30 19.163 70.813 -12.785
2021-06-30 25.193 81.698 -12.05

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBiotech Inc. (XBIT) Company Bio


XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.


XBIT Latest News Stream


Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream


Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | December 5, 2023

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

(Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for rheumatological diseases. The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Con

Yahoo | November 14, 2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutru

Yahoo | September 26, 2023

Individual investors account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) ownership, while insiders account for 35%

Key Insights The considerable ownership by individual investors in XBiotech indicates that they collectively have a...

Yahoo | September 16, 2023

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. Natrunix is indistinguishable from a naturally occurring antibody present in a healthy human. Natrunix binds and neutralizes a potent substance, a so called cytokine known as interleukin-1a (IL-1a),

Yahoo | August 30, 2023

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo 14.07%
3-mo 70.81%
6-mo 47.59%
1-year 103.32%
3-year -65.84%
5-year -42.08%
YTD 68.25%
2023 13.96%
2022 -68.46%
2021 -28.88%
2020 -16.15%
2019 267.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!